Persistent Expression of CD26/DPPIV After Treatment with Infliximab in Psoriasis Despite Clinical Improvement

Saved in:

Bibliographic Details
Published in:	Acta dermato-venereologica Vol. 89; no. 5; pp. 518 - 520
Main Authors:	VAN LINGEN, Rosanne G, VAN ERP, Piet E. J, SEYGER, Marieke M. B, DE JONG, Elke M. G. J, DE BOER-VAN HUIZEN, Roelie T, DRIESSEN, Rieke J. B, VAN DE KERKHOF, Peter C. M
Format:	Journal Article
Language:	English
Published:	Uppsala Acta dermato-venereologica 2009
Subjects:	Adult Antibodies, Monoclonal - therapeutic use Biological and medical sciences Biopsy Dermatologic Agents - therapeutic use Dermatology Dipeptidyl Peptidase 4 - metabolism Female Humans Infliximab Keratinocytes - drug effects Keratinocytes - immunology Keratinocytes - pathology Male Medical sciences Middle Aged Psoriasis - drug therapy Psoriasis - immunology Psoriasis - pathology Psoriasis. Parapsoriasis. Lichen Severity of Illness Index T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - pathology Time Factors Treatment Outcome Immunomodulator Skin disease Treatment Infliximab Psoriasis Dermatology Immunosuppressive agent
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Feature-1 ObjectType-Correspondence-3
ISSN:	0001-5555 1651-2057
DOI:	10.2340/00015555-0675